Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 124 entries
View as:

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04542369 Org: User:
Start: 05/01/21 End: 11/30/25 Due: 11/30/26

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06463171 Org: User:
Start: 06/30/24 End: 06/30/26 Due: 06/30/27

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05503667 Org: User:
Start: 02/01/22 End: 12/31/28 Due: 12/31/29

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Phase: N/A Priority: Normal
NCT ID: NCT06256237 Org: User:
Start: 04/01/24 End: 01/31/32 Due: 01/31/33

Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

Phase: N/A Priority: Normal
NCT ID: NCT02782312 Org: User:
Start: 06/30/11 End: 06/30/13 Due: 06/30/14

SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06480136 Org: User:
Start: 07/15/24 End: 02/15/28 Due: 02/15/29

Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis

Phase: N/A Priority: Normal
NCT ID: NCT03643263 Org: User:
Start: 06/25/18 End: 07/02/20 Due: 07/02/21

PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04539977 Org: User:
Start: 09/01/20 End: 12/31/28 Due: 12/31/29

Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05736991 Org: User:
Start: 11/01/22 End: 04/30/23 Due: 04/30/24

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04667793 Org: User:
Start: 01/31/21 End: 04/30/24 Due: 04/30/25

Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05881057 Org: User:
Start: 06/30/23 End: 06/30/28 Due: 06/30/29

Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT07020429 Org: User:
Start: 07/01/25 End: 07/30/30 Due: 07/30/31

Narrow Band Imaging (NBI) Under Electronic Bronchoscope in Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04676815 Org: User:
Start: 06/30/23 End: 07/31/24 Due: 07/31/25

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06648200 Org: User:
Start: 11/01/24 End: 09/01/30 Due: 09/01/31

Screening Microorganism of Cryptogenic Mechanical Pneumonia Through Next Generation Sequencing to Lung Tissue Fluid

Phase: N/A Priority: Normal
NCT ID: NCT04511884 Org: User:
Start: 08/07/20 End: 12/31/24 Due: 12/31/25

Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT04229121 Org: User:
Start: 01/15/20 End: 12/15/20 Due: 12/15/21

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase: N/A Priority: Normal
NCT ID: NCT06749886 Org: User:
Start: 11/19/24 End: 06/30/27 Due: 06/30/28

Research on New Regimens for Retreatment Pulmonary Tuberculosis

Phase: N/A Priority: Normal
NCT ID: NCT02331823 Org: User:
Start: 06/30/13 End: 12/31/16 Due: 12/31/17

The Role of KL-6 in the Clinical Diagnosis of ILD

Phase: N/A Priority: Normal
NCT ID: NCT02197364 Org: User:
Start: 12/31/13 End: 05/31/14 Due: 05/31/15

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06424821 Org: User:
Start: 07/04/23 End: 09/04/25 Due: 09/04/26

Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Phase: N/A Priority: Normal
NCT ID: NCT06093191 Org: User:
Start: 09/25/23 End: 12/30/25 Due: 12/30/26

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06837948 Org: User:
Start: 02/18/25 End: 12/01/31 Due: 12/01/32

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04379739 Org: User:
Start: 07/26/20 End: 12/30/26 Due: 12/30/27

Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03331588 Org: User:
Start: 11/10/17 End: 02/28/20 Due: 02/28/21

Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)

Phase: N/A Priority: Normal
NCT ID: NCT02509364 Org: User:
Start: 08/31/15 End: 09/30/17 Due: 09/30/18